Friday, November 24, 2006

AstraZeneca: Slapped Over Seroquel

According to a report today, the FDA fired a warning at AZ over Seroquel, their blockbuster treatment for bipolar disorder and schizophrenia. Here's what MarketWatch had to say:

According to the warning letter posted on the FDA Web site Wednesday, the sales material "minimizes the risk of hyperglycemia and diabetes mellitus and fails to communicate important information regarding neuroleptic malignant syndrome, tardive dyskinesia and the bolded cataracts precaution."

No comments: